perfluorohexyloctane · Bausch And Lomb Inc · NDA 216675

Miebo

Earliest generic entry, as listed
21 Jun 2037

Blocked by patent: US RE50060. Only method-of-use patents remain, so a generic may carve out the protected indication and enter earlier.

Listed patents · 9 unexpired

PatentClaimsExpires
US RE50060use U-458621 Jun 2037
US 10682315use U-458629 Sep 2036
US 11357738product29 Sep 2036
US 12128010product29 Sep 2036
US 10576154use U-19001 Oct 2035
US 10058615use U-190012 Sep 2033
US 10369117use U-190012 Sep 2033
US 10449164use U-190012 Sep 2033
US 12005033use U-458612 Sep 2033

Exclusivities · 1 unexpired

NCEnew chemical entity (5 years)18 May 2028

Paragraph IV certifications · 0

No Paragraph IV certification listed by FDA for this drug.

The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.

Event history

No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.

Products covered · 1

NDA · productFormStrengthListed expiry
216675 · 001 · RLDsolution/drops, ophthalmic1.338GM/ML21 Jun 2037